• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Clinical perspectives: Blood cholesterol treatment guidelines focus on four patient groups


Updated guidelines from the American College of Cardiology and American Heart Association.

A new guideline from the American College of Cardiology/American Heart Association on treatment of cholesterol in adults to reduce atherosclerotic cardiovascular disease (ASCVD) risk contains significant changes compared to the previous guideline in Adult Treatment Panel III Report published more than a decade ago.

Released in November 2013, the new guideline was developed in collaboration with the National Heart, Lung, and Blood Institute along with stakeholder and professional organizations. Recommendations were developed based on review of evidence from randomized controlled trials (RCTs) and systematic reviews and meta-analyses of RCTs investigating the effect of fixed doses of cholesterol-lowering medications for reducing ASCVD risk. 

NEXT: The importance of global risk assessment



Rather than focusing only on cholesterol levels to determine the appropriateness of statin use for primary prevention, the guidelines recommend performing global risk assessment using new pooled cohort equations to estimate the 10-year ASCVD risk. The latter includes blood cholesterol levels (total and HDL) along with patient age, gender, race, smoking status, systolic blood pressure, and whether the patient is receiving treatment for high blood pressure. The guideline notes that other factors, including family history, may be taken into account by the clinician for individualized decision-making.

The new guideline includes recommendations for safety monitoring in patients on statins and management of statin-related adverse events. It does not recommend specific targets for LDL- and/or non-HDL-cholesterol or the use of add-on therapy with non-statins, concluding that the latter medications do not provide acceptable ASCVD risk reduction benefits compared to their potential for adverse effects in routine prevention of ASCVD.

The guideline also reinforces the importance of practitioners applying their clinical judgment in management decisions and providing counseling on lifestyle issues (diet, exercise, weight, and tobacco use). 

Since most of the evidence used to formulate the recommendations is from 2011 and earlier, updating of the guideline was already planned to begin in 2014. 

Related Videos
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health